Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20443883 | 0.84 | ADRA1A (0.45) | ADRA1AADRB2ADRA2AADRA2BADRA2C | |
| SCHEMBL19249192 | 0.82 | GABRA1 (0.50) | ADRA1AADRB2ADRA2AADRA2BADRA2C | |
| SCHEMBL14951743 | 0.82 | GABRA1 (0.44) | ADRA1AADRB2ADRA2AADRA2BADRA2C | |
| SCHEMBL27956120 | 0.80 | ADRA1A (0.42) | ADRA1AADRB2ADRA2AADRA2BADRA2C | |
| SCHEMBL13005034 | 0.80 | GABRA1 (0.43) | ADRA1AADRB2ADRA2AADRA2BADRA2C | |
| SCHEMBL20711666 | 0.78 | LMNA (0.41) | ADRA1AADRB2ADRA2AADRA2BADRA2C | |
| SCHEMBL487169 | 0.78 | GABRA1 (0.56) | ADRA1AADRB2ADRA2AADRA2BADRA2C | |
| SCHEMBL9095132 | 0.78 | ADRA2A (0.58) | ADRA1AADRB2ADRA2AADRA2BADRA2C | |
| SCHEMBL9095138 | 0.78 | ADRA2A (0.58) | ADRA1AADRB2ADRA2AADRA2BADRA2C | |
| SCHEMBL12173269 | 0.77 | EIF4A3 (0.41) | ADRA1AADRB2ADRB1ADRB3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-26 | — | — | US | disclosed |
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9334289-B2 | Cephem compound having catechol or pseudo-catechol structure | SHIONOGI & CO., LTD. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-9290515-B2 | Cephem derivative having catechol group | SHIONOGI & CO., LTD (JP) | 2016-03-22 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20140256697-A1 | CEPHEM DERIVATIVE HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140088302-A1 | NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE | SHIONOGI & CO., LTD. (JP) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ADSL, SLC35B2, ADORA1 | ADRA1A 1269/4885ADRB2 1532/4885ADRA2A 1861/4885 |
| US-20140088302-A1 | NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE | COMT, CMBL, CEP170 | ADRA1A 1727/4885ADRB2 916/4885ADRA2A 2034/4885 |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | ADRA1A 3832/4885ADRB2 2846/4885ADRA2A 2852/4885 |
| US-20140256697-A1 | CEPHEM DERIVATIVE HAVING CATECHOL GROUP | COMT, CEP170, SLC6A3 | ADRA1A 771/4885ADRB2 602/4885ADRA2A 989/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | ADRA1A 3017/4885ADRB2 1492/4885ADRA2A 2726/4885 |
| US-10174053-B2 | 2 substituted cephem compounds | CEP170, CES2, CMBL | ADRA1A 3832/4885ADRB2 2846/4885ADRA2A 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.